US2005118112A1PendingUtilityA1

Treatment of Mycobacterial diseases by administration of bacterial/permeability-increasing protein products

32
Assignee: XOMA CORPPriority: Mar 12, 1993Filed: Sep 8, 2003Published: Jun 2, 2005
Est. expiryMar 12, 2013(expired)· nominal 20-yr term from priority
Inventors:Lewis H. Lambert, Jr.
Y10S530/827A61K 38/1751
32
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods for treating a subject suffering from infection with Mycobacteria , such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.

Claims

exact text as granted — not AI-modified
1 - 9 . (canceled)  
     
     
         10 . A method of treating a subject suffering from the adverse physiological effects of the presence of lipoarabinomannan in circulation, the method comprising administering to the subject a pharmaceutical composition comprising a BPI protein product selected from the group consisting of amino-terminal fragments of BPI holoprotein having a molecular weight of 21-25 kD by SDS-PAGE and dimeric forms thereof, rBPI 21 , rBPI 23 , rBPI and BPI-derived peptides, or fusion protein comprising said BPI protein product, and a pharmaceutically acceptable diluent, adjuvant, or carrier.  
     
     
         11 . The method of  claim 10  wherein the adverse physiological effects comprise compromised immune response to microbes or tumor cells due to lipoarabinomannan-induced inhibition of macrophage activation by T-cell lymphokines.  
     
     
         12 . The method of  claim 10  wherein the adverse physiological effects comprise increased production of a cytokine by the subject.  
     
     
         13 . The method of  claim 10  wherein the composition is administered orally.  
     
     
         14 . The method of  claim 10  wherein the composition is administered intravenously.  
     
     
         15 . The method of  claim 10  wherein the composition is administered as an aerosol.  
     
     
         16 . The method of  claim 10  wherein the BPI protein product is a 21-25 kD amino-terminal fragment of Bactericidal/permeability-increasing protein.  
     
     
         17 . The method of  claim 10 , wherein the composition further comprises a surfactant.  
     
     
         18 - 23 . (canceled)

Join the waitlist — get patent alerts

Track US2005118112A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.